- Home
- TDTH vs XLO Comparison
TDTH vs XLO Comparison
Compare TDTH & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDTH
- XLO
- Stock Information
- Founded
- TDTH 2014
- XLO 2016
- Country
- TDTH Singapore
- XLO United States
- Employees
- TDTH N/A
- XLO N/A
- Industry
- TDTH
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- TDTH
- XLO Health Care
- Exchange
- TDTH NYSE
- XLO Nasdaq
- Market Cap
- TDTH 42.7M
- XLO 42.2M
- IPO Year
- TDTH 2024
- XLO 2021
- Fundamental
- Price
- TDTH $0.36
- XLO $0.70
- Analyst Decision
- TDTH
- XLO Buy
- Analyst Count
- TDTH 0
- XLO 1
- Target Price
- TDTH N/A
- XLO $4.00
- AVG Volume (30 Days)
- TDTH 914.5K
- XLO 2.9M
- Earning Date
- TDTH 06-10-2025
- XLO 05-08-2025
- Dividend Yield
- TDTH N/A
- XLO N/A
- EPS Growth
- TDTH N/A
- XLO N/A
- EPS
- TDTH N/A
- XLO N/A
- Revenue
- TDTH $465,435.00
- XLO $9,274,000.00
- Revenue This Year
- TDTH N/A
- XLO $299.61
- Revenue Next Year
- TDTH N/A
- XLO $1.99
- P/E Ratio
- TDTH N/A
- XLO N/A
- Revenue Growth
- TDTH N/A
- XLO N/A
- 52 Week Low
- TDTH $0.20
- XLO $0.62
- 52 Week High
- TDTH $4.74
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- TDTH N/A
- XLO 44.41
- Support Level
- TDTH N/A
- XLO $0.86
- Resistance Level
- TDTH N/A
- XLO $1.15
- Average True Range (ATR)
- TDTH 0.00
- XLO 0.11
- MACD
- TDTH 0.00
- XLO 0.00
- Stochastic Oscillator
- TDTH 0.00
- XLO 5.34
About TDTH TRIDENT DIGITAL TECH HOLDINGS LTD SPON ADS EACH REP 8 ORD CL B
Trident Digital Tech Holdings is principally engaged in the provision of business consulting service and IT customization solutions in the Republic of Singapore.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).